NO20092609L - Tannate salt of rasagiline - Google Patents

Tannate salt of rasagiline

Info

Publication number
NO20092609L
NO20092609L NO20092609A NO20092609A NO20092609L NO 20092609 L NO20092609 L NO 20092609L NO 20092609 A NO20092609 A NO 20092609A NO 20092609 A NO20092609 A NO 20092609A NO 20092609 L NO20092609 L NO 20092609L
Authority
NO
Norway
Prior art keywords
rasagiline
tannate salt
tannate
salt
rasagilin
Prior art date
Application number
NO20092609A
Other languages
English (en)
Norwegian (no)
Inventor
Tamas Koltai
Anton Frenkel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20092609L publication Critical patent/NO20092609L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20092609A 2006-12-14 2009-07-08 Tannate salt of rasagiline NO20092609L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
NO20092609L true NO20092609L (no) 2009-09-04

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092609A NO20092609L (no) 2006-12-14 2009-07-08 Tannate salt of rasagiline

Country Status (24)

Country Link
US (1) US7547806B2 (sr)
EP (1) EP2101570B1 (sr)
JP (1) JP5356248B2 (sr)
KR (1) KR101077835B1 (sr)
CN (1) CN101600346B (sr)
AU (1) AU2007334493B2 (sr)
BR (1) BRPI0718339A2 (sr)
CA (1) CA2672452C (sr)
DK (1) DK2101570T3 (sr)
EA (1) EA016843B1 (sr)
ES (1) ES2420124T3 (sr)
HK (1) HK1129277A1 (sr)
HR (1) HRP20130396T1 (sr)
IL (1) IL198984A (sr)
MX (1) MX2009006252A (sr)
NO (1) NO20092609L (sr)
NZ (1) NZ577623A (sr)
PL (1) PL2101570T3 (sr)
PT (1) PT2101570E (sr)
RS (1) RS52784B (sr)
SI (1) SI2101570T1 (sr)
UA (1) UA97382C2 (sr)
WO (1) WO2008076315A1 (sr)
ZA (1) ZA200903904B (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507586A (ja) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
MX2007010233A (es) * 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
WO2007061717A2 (en) * 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
WO2007098264A2 (en) * 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
PL2101569T3 (pl) * 2006-12-14 2012-03-30 Teva Pharma Stała, krystaliczna zasada rasagaliny
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
AU2009258151A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for Parkinson's disease modification
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
WO2011080589A2 (en) 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
CA2851276A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
JP6523328B2 (ja) * 2014-04-17 2019-05-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． タンニン酸シタグリプチン複合体
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
HU229507B1 (en) 1996-12-18 2014-01-28 Technion Res & Dev Foundation 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
EP1628656B1 (en) * 2003-03-25 2008-10-15 Kiel Laboratories, Inc. Gabapentin tannate in liquid and/or semi-solid dosage forms
WO2005023257A1 (en) * 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
WO2005025573A1 (en) * 2003-09-05 2005-03-24 P3 Laboratories, Inc. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
JP2008507586A (ja) 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
MX2007006199A (es) 2004-11-24 2007-07-13 Teva Pharma Composiciones de desintegracion oral de rasagilina.
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
WO2007061717A2 (en) 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
ES2420124T3 (es) 2013-08-22
AU2007334493A1 (en) 2008-06-26
SI2101570T1 (sl) 2013-06-28
CN101600346B (zh) 2013-08-21
PT2101570E (pt) 2013-05-17
IL198984A (en) 2013-03-24
KR101077835B1 (ko) 2011-10-28
ZA200903904B (en) 2010-08-25
CN101600346A (zh) 2009-12-09
EA200970580A1 (ru) 2009-12-30
AU2007334493B2 (en) 2010-12-02
JP5356248B2 (ja) 2013-12-04
EA016843B1 (ru) 2012-07-30
KR20090088433A (ko) 2009-08-19
PL2101570T3 (pl) 2013-07-31
JP2010513280A (ja) 2010-04-30
WO2008076315A1 (en) 2008-06-26
MX2009006252A (es) 2009-10-13
RS52784B (sr) 2013-10-31
UA97382C2 (ru) 2012-02-10
CA2672452C (en) 2012-07-03
IL198984A0 (en) 2010-02-17
US20080146676A1 (en) 2008-06-19
DK2101570T3 (da) 2013-05-27
EP2101570A4 (en) 2011-04-06
HRP20130396T1 (en) 2013-06-30
EP2101570B1 (en) 2013-02-13
CA2672452A1 (en) 2008-06-26
HK1129277A1 (en) 2009-11-27
EP2101570A1 (en) 2009-09-23
BRPI0718339A2 (pt) 2014-02-18
US7547806B2 (en) 2009-06-16
NZ577623A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
NO20092609L (no) Tannate salt of rasagiline
NO20092611L (no) Krystallinsk faststoff Rasagilin base
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
NO20083153L (no) Kjemiske forbindelser
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
JO2778B1 (en) Certain vehicles, installations and methods
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
MY153915A (en) Organic compounds
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2009004813A (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
FR2934863B1 (fr) Copolyamide semi-aromatique et son procede de preparation
EA200801199A1 (ru) Ингибиторы киназы
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
EA201170483A1 (ru) Твердая фармацевтическая композиция
MX2009009490A (es) Profarmacos novedosos.
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
WO2008051539A3 (en) Processes for preparing palonosetron salts
EA201000069A1 (ru) Новые гербициды
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
TW200638932A (en) CCI-779 polymorph and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application